|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 750 9th Street, NW |
Address2 | Suite 575 |
City | Washington |
State | DC |
Zip Code | 20001-4584 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 57954-12
|
||||||||
|
6. House ID# 352640002
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Andrea Wilkinson, Director, Federal Governmental Affairs |
Date | 07/20/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm., Cong. McCrery |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance health reformoptions
H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm., Cong. McCrery |
|
Laura |
Cline |
|
|
|
Deborah |
Walter |
|
MedPAC |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-biologic issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm, Cong. McCrery |
|
Laura |
Cline |
|
|
|
Deborah |
Walter |
|
MedPAC |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance Committee Roundtable health reform options,
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Agency for Health Care Policy & Research, Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm., Cong. McCrery |
|
Laura |
Cline |
|
|
|
Deborah |
Walter |
|
MedPAC |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm., Cong. McCrery |
|
Laura |
Cline |
|
|
|
Deborah |
Walter |
|
MedPAC |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senator McCain Importation Amendment
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm., Cong. McCrery |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
H.R. 1262 Water Quality Investment Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm., Cong. McCrery |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
H.R. 1346/S. 540 The Medical Device Safety Act
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
Sen. Breaux, House MMF Comm., Cong. McCrery |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |